links.lww.com/MD/C200

Supplementary table 1 Re-analysis of correlations of uMCP-1,uTWEAK and other parameters

　 　 uMCP-1 　 　 　 uTWEAK 　 　

　 　 N rs Sig. （ Two- tail）

N rs Sig. （ Two-

tail）

rSLEDAI 32 0.497 0.004** 32 0.331 0.044*

SLEDAI 25 0.287 0.164 25 0.042 0.843

24hr UP 32 0.435 0.013* 32 0.411 0.019*

Cys-C 32 0.012 0.949 32 -0.135 0.462

Cr 32 -0.132 0.471 32 -0.092 0.616

BuN 32 0.001 0.994 32 0.025 0.892

sIgG 32 0.090 0.624 32 -0.136 0.457

sIgA 32 0.081 0.659 32 0.188 0.302

sIgM 32 -0.231 0.204 32 -0.074 0.689

ESR 32 0.233 0.198 32 0.235 0.195

C3 32 -0.441 0.011* 32 0.122 0.506

C4 32 -0.422 0.016* 32 0.076 0.679

anti-C1q antibodies

28 0.350 0.068 28 0.008 0.968

anti-dsDNA antibodies

32 0.384 0.03* 32 0.157 0.391

ANA 32 -0.183 0.316 32 0.033 0.858

GFR 8 0.167 0.693 8 0.095 0.823

sβ2MG 28 0.177 0.369 28 0.002 0.992

uβ2MG 29 0.202 0.293 29 -0.021 0.912

uAlb 29 0.414 0.026* 29 0.124 0.520

uIgG 28 0.304 0.116 28 -0.130 0.510

uα1MG 29 -0.044 0.819 29 -0.199 0.300

uTWEAK 32 0.388 0.028* - - -

** p <0.01 and *p<0.05

uMCP-1 urinary Monocyte Chemoattractant Protein-1, uTWEAK, urinary Tumor necrosis factor- like inducer of apoptosis, SLEDAI Systemic Lupus Erythematosus Disease Activity Index, 24hr UP, 24 hour Urine Proteinuria, Cys-C Cystatin C, Cr Creatinine, BuN Blood Urea Nitrogen, sIgG Serum Immunoglobulin-Gamma, sIgA Serum Immunoglobulin-Alpha, sIgM Serum Immunoglobulin-Mu, ESR Erythrocyte Sedimentation Rate, C3 Complement 3, C4 Complement 4, anti-C1q antibodies, Anti-Complement 1q antibodies, Anti-dsDNA antibodies anti-double strand DNA antibodies, ANA Antinuclear Antibody; GFR Glomerular Filtration Rate, sβ2MG serum beta-2 microglobulin, uβ2MG urinary beta-2 microglobulin; uAlb urinary Albumin, uIgG urinary Immunoglobulin-gamma, uα1MG urinary alpha-1 microglobulin

Supplementary table 2 Re-analysis of Sensitivity and specificity to assess proteinuria with uMCP-1 and uTWEAK

AUC (95% CI) Cut-off value Sensitivity (%) Specificity (%)

Youde n index

uMCP-1 0.745 (0.578,0.911) 170.01 58.3 100 0.583

uTWEAK 0.635 (0.109,0.258) 29.13 29.2 100 0.292

uACR 0.839(0.689,0.988) 15.56 79.2 87.5 0.667

Combined model^†

0.792(0.639,0.945) 9.64 70.8 100 0.708

†The combined model was acquired using the following algorithm.

Y=0.07*uMCP+0.22*uTWEAK-3.72

AUC Area Under ROC curve, 24hr UP 24-hour Urine Proteinuria, uMCP-1 urinary Monocyte Chemoattractant Protein-1, uTWEAK urinary Tumor necrosis factor-like inducer of apoptosis

Supplementary material:

Supplementary figure 1 Distribution of uMCP-1, uTWEAK, and uACR in different

groups of patients. (A) Subgroup analysis of uMCP-1 in class V, class V+III, class V+IV patients. (B) Subgroup analysis of uTWEAK in class V, class V+III, class V+IV patients. (C) uMCP-1 significantly elevated in renal active patients compared with inactive patients (p<0.001). (D) uMCP-1 significantly elevated in renal active patients compared with inactive patients (p<0.001). (E) Elevation of uACR was insignificant in renal active patients compared with inactive patients (p>0.05).

rSLEDAI, renal Systemic Lupus Erythematosus Disease Activity Index; uMCP-1,

urinary Monocyte Chemoattractant Protein-1; uTWEAK, urinary Tumor necrosis

factor-like inducer of apoptosis; uACR, urine Albumin/Creatinine Ratio

Supplementary figure 2 Subgroup analysis of Receiver-operation characteristic curves of uMCP-1, uTWEAK, uACR and combined model in assessing proteinuria.

The black dotted, grey dotted and grey solid ROC curves represented uMCP-1, uTWEAK and uACR respectively. The black solid ROC curve represented the combined model of uTWEAK, uMCP-1. The AUC (Area under ROC curves) of the combined model was larger than those of the uMCP or uTWEAK (0.792 versus 0.745 or 0.635). AUC of uACR was larger than other models (0.839).

uMCP-1, urinary Monocyte Chemoattractant Protein-1; uTWEAK, urinary Tumor

necrosis factor-like inducer of apoptosis; uACR, urine Albumin/Creatinine Ratio

Combined model: Y=0.07*uMCP+0.22*uTWEAK-3.72